Esophageal Tumor - Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Esophageal Tumor - Pipeline Review, H2 2012', provides an overview of the Esophageal Tumor therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Esophageal Tumor. 'Esophageal Tumor - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Reasons to buy
Keywords
Esophageal Tumor Therapeutic Products under Development, Key Players in Esophageal Tumor Therapeutics, Esophageal Tumor Pipeline Overview, Esophageal Tumor Pipeline, Esophageal Tumor Pipeline Assessment
Summary
Global Markets Direct’s, 'Esophageal Tumor - Pipeline Review, H2 2012', provides an overview of the Esophageal Tumor therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Esophageal Tumor. 'Esophageal Tumor - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Esophageal Tumor.
- A review of the Esophageal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Esophageal Tumor pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Esophageal Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Esophageal Tumor pipeline depth and focus of Esophageal Tumor therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Esophageal Tumor Therapeutic Products under Development, Key Players in Esophageal Tumor Therapeutics, Esophageal Tumor Pipeline Overview, Esophageal Tumor Pipeline, Esophageal Tumor Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Esophageal Tumor Overview
Therapeutics Development
An Overview of Pipeline Products for Esophageal Tumor
Esophageal Tumor Therapeutics under Development by Companies
Esophageal Tumor Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Esophageal Tumor Therapeutics – Products under Development by Companies
Esophageal Tumor Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Esophageal Tumor Therapeutics Development
Proteo, Inc.
Esophageal Tumor – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Elafin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPPH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Esophageal Tumor Therapeutics – Drug Profile Updates
Esophageal Tumor Therapeutics - Dormant Products
Esophageal Tumor – Product Development Milestones
Featured News & Press Releases
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Esophageal Tumor, H2 2012
Products under Development for Esophageal Tumor – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Proteo, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Esophageal Tumor Therapeutics – Drug Profile Updates
Esophageal Tumor Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Esophageal Tumor, H2 2012
Products under Development for Esophageal Tumor – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Mid Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Esophageal Tumor Overview
Therapeutics Development
An Overview of Pipeline Products for Esophageal Tumor
Esophageal Tumor Therapeutics under Development by Companies
Esophageal Tumor Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Esophageal Tumor Therapeutics – Products under Development by Companies
Esophageal Tumor Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Esophageal Tumor Therapeutics Development
Proteo, Inc.
Esophageal Tumor – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Elafin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPPH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Esophageal Tumor Therapeutics – Drug Profile Updates
Esophageal Tumor Therapeutics - Dormant Products
Esophageal Tumor – Product Development Milestones
Featured News & Press Releases
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Esophageal Tumor, H2 2012
Products under Development for Esophageal Tumor – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Proteo, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Esophageal Tumor Therapeutics – Drug Profile Updates
Esophageal Tumor Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Esophageal Tumor, H2 2012
Products under Development for Esophageal Tumor – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Mid Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
